Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment
Open Access
- 15 October 2024
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 26 (12) , 707-719
Abstract
Purpose of the Review: This review discusses the molecular mechanisms involved in the immuno-pathogenesis of atherosclerosis, the pleiotropic anti-inflammatory effects of approved cardiovascular therapies and the available evidence on immunomodulatory therapies for atherosclerotic cardiovascular disease (ACVD). We highlight the importance of clinical and translational research in identifying molecular mechanisms and discovering new therapeutic targets. Recent Findings: The CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) trial was the first to demonstrate a reduction in cardiovascular (CV) risk with anti-inflammatory therapy, irrespective of serum lipid levels. Summary: ACVD is the leading cause of death worldwide. Although targeting principal risk factors significantly reduces CV risk, residual risk remains unaddressed. The immunological mechanisms underlying atherosclerosis represent attractive therapeutic targets. Several commonly used and non-primarily anti-inflammatory drugs (i.e. SGLT2i, and PCSK9i) exhibit pleiotropic properties. Otherwise, recent trials have investigated the blockade of primarily inflammatory compounds, trying to lower the residual risk via low-dose IL-2, PTPN22 and CD31 pathway modulation. In the era of precision medicine, modern approaches may explore new pharmacological targets, identify new markers of vascular inflammation, and evaluate therapeutic responses.Keywords
Funding Information
- Università Cattolica del Sacro Cuore
This publication has 80 references indexed in Scilit:
- Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarctionAmerican Heart Journal, 2024
- Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte RatioJAMA Cardiology, 2022
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial InfarctionJAMA, 2022
- Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical TranslationCurrent Atherosclerosis Reports, 2018
- Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial InfarctionJAMA, 2016
- Effect of Darapladib on Major Coronary Events After an Acute Coronary SyndromeJAMA, 2014
- Varespladib and Cardiovascular Events in Patients With an Acute Coronary SyndromeJAMA, 2014
- Relation of Baseline High-Sensitivity C-Reactive Protein Level to Cardiovascular Outcomes With Rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)The American Journal of Cardiology, 2010
- Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)The American Journal of Cardiology, 2010
- Effects of a 5-Lipoxygenase–Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial InfarctionJAMA, 2005